Cytokinetics (CYTK) Set to Announce Earnings on Thursday

Share on StockTwits

Cytokinetics (NASDAQ:CYTK) is scheduled to be releasing its earnings data after the market closes on Thursday, November 1st. Analysts expect Cytokinetics to post earnings of ($0.53) per share for the quarter.

Cytokinetics stock opened at $6.60 on Wednesday. The company has a current ratio of 8.95, a quick ratio of 8.95 and a debt-to-equity ratio of 0.41. The company has a market cap of $369.83 million, a price-to-earnings ratio of -2.55 and a beta of 1.42. Cytokinetics has a fifty-two week low of $6.20 and a fifty-two week high of $14.30.

In other news, CEO Robert I. Blum sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $7.94, for a total value of $31,760.00. Following the sale, the chief executive officer now directly owns 164,022 shares of the company’s stock, valued at approximately $1,302,334.68. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last three months, insiders sold 16,500 shares of company stock worth $129,505. Insiders own 5.10% of the company’s stock.

Several research firms have weighed in on CYTK. BidaskClub raised Cytokinetics from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 28th. Zacks Investment Research raised Cytokinetics from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a research report on Saturday, July 14th. ValuEngine raised Cytokinetics from a “hold” rating to a “buy” rating in a research report on Wednesday, October 3rd. Morgan Stanley set a $10.00 price objective on Cytokinetics and gave the company a “hold” rating in a research report on Friday, October 5th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 price target on shares of Cytokinetics in a research report on Wednesday, October 3rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $13.00.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.

Featured Article: What do investors mean by earnings per share?

Earnings History for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with's FREE daily email newsletter.

Leave a Reply